Measles and rubella vaccine - Biological E. Limited/Takeda

Drug Profile

Measles and rubella vaccine - Biological E. Limited/Takeda

Latest Information Update: 13 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biological E Limited
  • Developer Biological E Limited; Takeda
  • Class Measles vaccines; Rubella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Measles; Rubella

Most Recent Events

  • 26 Jun 2017 Biological E Limited in-licenses measles vaccine technology from Takeda
  • 26 Jun 2017 Early research in Measles and Rubella (Prevention) in India (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top